MetaCap

Foghorn Therapeutics (FHTX) vs Genelux (GNLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Genelux (GNLX) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 56.3% versus a loss of 62.8%. Genelux is the larger company by market cap ($103.4 million vs $103.1 million), about 1.0 times the size, while Foghorn Therapeutics is growing revenue faster (+36.8% vs +0.0%). Foghorn Therapeutics converts more of its revenue into profit, with a net margin of -240.3% versus -401812.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FHTX-62.77%GNLX-56.25%
+59%-5%-69%
Nov 21, 20251 yearNov 20, 2026
FHTX-79.79%GNLX-63.89%
+510%+201%-108%
Jan 23, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FHTX versus GNLX key metrics
MetricFHTXGNLX
Share price$1.72$2.17
Market cap$103.14M$103.36M
1-day change-3.37%-4.82%
YTD return-68.15%-50.23%
1-year return-62.77%-56.25%
5-year return-87.36%—
P/E ratio (TTM)19.11—
EPS (TTM)$0.09$-0.88
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$30.91M$8.00K
Revenue growth (YoY)+36.75%0.00%
Net income (latest FY)$-74.28M$-32.15M
Operating margin-279.49%-415175.00%
Net margin-240.33%-401812.50%
52-week high$7.61$5.89
52-week low$1.66$1.77
Distance from 52-week high-77.40%-63.16%
Analyst consensusbuystrong_buy
Avg. price target upside+142.44%+767.74%
Average volume843.73K333.31K
Shares outstanding59.96M47.63M
Employees10625
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Foghorn Therapeutics is more profitable, keeping -240.3 cents of every revenue dollar as net income versus -401812.5 cents for Genelux.
  • Foghorn Therapeutics grew revenue faster in its latest fiscal year (+36.75% vs 0.00%).

About Foghorn Therapeutics

FHTX stock →

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

About Genelux

GNLX stock →

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

FHTX vs GNLX FAQ

Which is bigger, Foghorn Therapeutics or Genelux?

Genelux (GNLX) is larger, with a market capitalization of $103.36M compared with $103.14M for Foghorn Therapeutics (FHTX).

Which stock has performed better over the past year, FHTX or GNLX?

GNLX returned -56.25% over the past 12 months, compared with -62.77% for FHTX (price return, excluding dividends). Past performance does not predict future results.

Are Foghorn Therapeutics and Genelux in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons